Phibro Animal Health Earnings Call: Key Takeaways
Phibro delivered 6% revenue growth and 11% net income growth in Q1, maintaining FY2027 guidance despite margin pressure in animal health and regulatory delays in Brazil.
- Call
- Nov 5, 2026, 9:00 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Phibro Animal Health Corp filings on SEC EDGAR ↗
Filing type
Alerts
Time
4 alerts with these filters
Phibro delivered 6% revenue growth and 11% net income growth in Q1, maintaining FY2027 guidance despite margin pressure in animal health and regulatory delays in Brazil.
Phibro Animal Health reported Q1 2027 net sales of $386.8 million, a 6% increase year-over-year, driven by growth in Mineral Nutrition and Performance Products. The company maintained its full-year fiscal 2027 guidance despite regulatory headwinds for virginiamycin in Brazil. Additionally, shareholders ratified the election of three Class I directors and the appointment of PwC as auditors at the annual meeting.
“First quarter results exceeded our expectations and grew on top of a strong first quarter last year. The outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products while our core Animal Health business delivered sales in line with our plan and Adjusted EBITDA ahead of plan, including the benefit of certain costs that shifted into the second quarter.”
Dani Bendheim, President and Chief Executive Officer
“Improving working capital and cash conversion is a top priority, and we are committed to delivering meaningful progress during fiscal 2027.”
Dani Bendheim, President and Chief Executive Officer
Phibro Animal Health Corp reported net sales of $386.8 million for the quarter ended September 30, 2026, a 6% increase compared to the prior year. Net income rose to $29.5 million ($0.72 per diluted share) from $26.5 million, driven by higher sales volume and improved foreign currency impacts despite an increase in selling, general, and administrative expenses.
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on December 16, 2026, to stockholders of record as of November 25, 2026.